Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.
Advanced Therapy Medicinal Products Contract Development And Manufacturing Organization (CDMO) Market Forecast: What Market Value Is Expected By 2030?
The market for contract development and manufacturing organizations (CDMOs) specializing in advanced therapy medicinal products has experienced significant expansion recently, poised to escalate from $6.2 billion in 2025 to $7.24 billion in 2026, reflecting a compound annual growth rate (CAGR) of 16.7%. This robust growth trajectory during the historical period was fueled by several key factors, including the constrained supply of dedicated CDMO capabilities, elevated research and development expenditures within the advanced therapies sector, early adoption of gene and cell-based treatments, an increase in the incidence of intricate medical conditions, and the burgeoning presence of small biotechnology firms.
The market for contract development and manufacturing organizations (CDMOs) specializing in advanced therapy medicinal products is poised for substantial expansion in the upcoming years, projecting a valuation of $12.55 billion by 2030 with a compound annual growth rate (CAGR) of 14.8%. This anticipated growth trajectory is fueled by several key factors, including progress in manufacturing technologies that enable scalability, a rise in partnerships between CDMOs and pharmaceutical companies, the increasing prevalence of both autologous and allogeneic therapies, a growing worldwide need for personalized medical treatments, and the extension of services into developing markets. Significant trends shaping this period involve a heightened requirement for CDMO expertise in advanced therapy development, the broadening scope of gene-, cell-, and tissue-engineered therapies, a greater emphasis on adhering to regulatory requirements and quality benchmarks, an increase in outsourced manufacturing by biopharmaceutical firms, and the adoption of adaptable and scalable production methodologies.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15719&type=smp
Advanced Therapy Medicinal Products Contract Development And Manufacturing Organization (CDMO) Market Expansion Supported By Key Demand Factors
The expansion of the advanced therapy medicinal products CDMO market is anticipated to be significantly boosted by the growing volume of clinical trials. These trials, essential for evaluating the safety and effectiveness of new medical approaches, are experiencing an upward trend due to the escalating need for novel therapies and the rising prevalence of diseases worldwide. As the utilization of advanced therapy medicinal products increases, so does the demand for specialized CDMO manufacturing capabilities, which offer the necessary expertise and facilities. Furthermore, the insights gained from clinical trial data are instrumental in refining manufacturing processes, enabling efficient scaling, and upholding quality standards to satisfy escalating clinical and commercial requirements. Illustratively, the Royal Pharmaceutical Society reported that in the UK, patient enrollment in clinical trials reached 349,019 during 2023/2024, a rise from the 342,390 individuals participating in 2022/2023, underscoring the dynamic growth in trial activity which, in turn, fuels the advanced therapy medicinal products CDMO market’s expansion.
Advanced Therapy Medicinal Products Contract Development And Manufacturing Organization (CDMO) Market Segment Landscape: Which Areas Lead Market Development?
The advanced therapy medicinal products contract development and manufacturing organization (cdmo) market covered in this report is segmented –
1) By Product: Gene Therapy, Cell Therapy, Tissue Engineered
2) By Phase: Phase I, Phase II, Phase III, Phase IV
3) By Indication: Oncology, Cardiology, Central Nervous System And Musculoskeletal, Infectious Disease, Dermatology, Endocrine, Metabolic, Genetic, Immunology And Inflammation, Ophthalmology, Hematology
Subsegments:
1) By Gene Therapy: Viral Vectors, Non-Viral Vectors, Dna Or Rna-Based Products
2) By Cell Therapy: Autologous Cell Therapy, Allogeneic Cell Therapy, Stem Cell Therapy
3) By Tissue Engineered: Skin Substitutes, Cartilage And Bone Tissue, Vascular Grafts And Organs
Advanced Therapy Medicinal Products Contract Development And Manufacturing Organization (CDMO) Market Growth Trends Influencing Competitive Dynamics
Leading entities within the advanced therapy medicinal products CDMO sector are actively enhancing their cell therapy production capabilities to address significant challenges inherent in cell therapy manufacturing and to accelerate the progression of their collaborators’ projects. These cell therapy manufacturing services, provided by contract development and manufacturing organizations, encompass a broad spectrum of support, extending from initial preclinical research through to late-stage clinical investigations and eventual market launch. As an illustration, in January 2024, Pluristem Therapeutics Inc., an Israeli biotechnology firm specializing in cellular solutions, introduced PluriCDMO, a newly established business unit dedicated to cell therapy manufacturing. This division employs an proprietary bioreactor technology designed for three-dimensional cell expansion, enabling the generation of diverse cell populations including stem cells, induced pluripotent stem cells, exosomes, and immune-based therapies. PluriCDMO aims to deliver essential, high-quality therapeutics to patients by ensuring unparalleled batch-to-batch uniformity within a scalable, economically viable, and regulated good manufacturing practice environment.
Advanced Therapy Medicinal Products Contract Development And Manufacturing Organization (CDMO) Market Industry Leaders And Market Competition
Major companies operating in the advanced therapy medicinal products contract development and manufacturing organization (cdmo) market are Thermo Fisher Scientific Inc., Merck KGaA, Lonza Group AG, Catalent Inc., Charles River Laboratories International Inc., Recipharm AB, KBI Biopharma, Takara Bio Inc., Rentschler Biopharma SE, Ajinomoto Co. Inc., ElevateBio LLC, Fujifilm Diosynth Biotechnologies, Axplora Group GmbH, WuXi Advanced Therapies Inc., Celonic Group, Batavia Biosciences B.V., BioCentriq, Cytovance Biologics, Andelyn Biosciences, Genezen, AGC Biologics, ABL Manufacturing, Minaris Regenerative Medicine, Porton Advanced Solutions
Access The Complete Advanced Therapy Medicinal Products Contract Development And Manufacturing Organization (CDMO) Market Report:
Advanced Therapy Medicinal Products Contract Development And Manufacturing Organization (CDMO) Market Regional Outlook: Where Are The Largest Opportunities Located?
North Americawas the largest region in the advanced therapy medicinal product contract development and manufacturing organization (CDMO) market in 2025. Asia-Pacificis expected to be the fastest-growing region in the forecast period. The regions covered in the advanced therapy medicinal products contract development and manufacturing organization (cdmo) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
